Tolvaptan for Volume Management in Heart Failure

Pharmacotherapy
Erik G GundersonTheodore J Berei

Abstract

Volume management in acute decompensated and chronic heart failure (HF) remains a significant challenge. Although progress has been made in the development of mortality-reducing neurohormonal regimens in the reduced ejection fraction population, no clinical trial has yet demonstrated anything more than symptomatic relief or biomarker reduction with pharmacotherapeutic volume-based interventions made in the acutely decompensated individual or those with evolving outpatient congestion. As the number of patients with HF continues to grow, in addition to HF-related hospitalizations, identifying therapies that have the potential to aid in diuresis more safely and efficaciously is paramount to decreasing inpatient length of stay and preventing unnecessary admissions. More recently, a significant amount of research has been dedicated to the use of vasopressin antagonists, specifically tolvaptan, as adjunctive therapy to loop and thiazide diuretics. Although these agents do not seem to have a pervasive role in fluid management in the acute decompensated and chronic HF populations, they are effective tools to have available for specific clinical situations. This review summarizes the literature surrounding the use of tolvaptan for volum...Continue Reading

References

Nov 5, 2003·Gastroenterology·UNKNOWN American Gastroenterological Association Clinical Practice Committee
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Douglas S LeeJack V Tu
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Sep 29, 2005·American Journal of Physiology. Renal Physiology·Lisa C Costello-BoerrigterJohn C Burnett
Nov 16, 2005·Journal of the American College of Cardiology·Steven R Goldsmith, Mihai Gheorghiade
Apr 11, 2006·European Heart Journal·Luigi TavazziUNKNOWN Italian survey on Acute Heart Failure Investigators
Nov 16, 2006·The New England Journal of Medicine·Robert W SchrierUNKNOWN SALT Investigators
Nov 23, 2006·The American Journal of Medicine·Mihai GheorghiadeJohn Burnett
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Oct 10, 2007·Journal of Cardiac Failure·Kevin DammanHans L Hillege
Mar 4, 2011·The New England Journal of Medicine·G Michael FelkerUNKNOWN NHLBI Heart Failure Clinical Research Network
Dec 20, 2012·Circulation. Heart Failure·Robb D KociolUNKNOWN NHLBI Heart Failure Network Steering Committee and Investigators
Mar 21, 2013·Circulation. Heart Failure·Dmitry Y ShchekochikhinNicolaos E Madias
Nov 20, 2013·JAMA : the Journal of the American Medical Association·Horng H ChenUNKNOWN NHLBI Heart Failure Clinical Research Network
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Aug 2, 2015·Cellular Signalling·Melissa A WasilewskiDouglas G Tilley
Dec 18, 2015·Circulation·UNKNOWN Writing Group MembersUNKNOWN Stroke Statistics Subcommittee
Feb 27, 2016·Journal of Cardiac Failure·Yuya MatsueSteven R Goldsmith
Sep 23, 2016·Journal of the American College of Cardiology·G Michael FelkerChristopher M O'Connor
Mar 18, 2017·Journal of the American College of Cardiology·Marvin A KonstamUNKNOWN SECRET of CHF Investigators, Coordinators, and Committee Members
Jul 21, 2017·Cardiology Research·Poornima VinodRupesh Raina
Oct 1, 2015·Cardiac Failure Review·Pierpaolo PellicoriAndrew L Clark
Aug 9, 2017·Cardiac Failure Review·Gianluigi Savarese, Lars H Lund
Aug 25, 2017·Circulation Journal : Official Journal of the Japanese Circulation Society·Takayuki InomataUNKNOWN Kanagawa Aquaresis Investigators
Feb 2, 2018·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Dec 28, 2018·ClinicoEconomics and Outcomes Research : CEOR·Kathryn FitchWilliam S Weintraub
Jan 11, 2019·Journal of Clinical Medicine Research·Tomohiko YamamotoHidenori Urata

❮ Previous
Next ❯

Citations

Jul 20, 2019·Journal of Gastroenterology and Hepatology·Ioannis BellosDespina N Perrea

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved